Insys Therapeutics, Inc.
INSY announced today that it has received a subpoena from
the Office of Inspector General of the Department of Health and Human
Services ("HHS") in connection with an investigation of potential
violations involving HHS programs. The subpoena requests documents
regarding Subsys(R), including Insys' sales and marketing practices
relating to this product. Insys intends to cooperate with the
investigation.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a
commercial-stage specialty pharmaceutical company that develops and
commercializes innovative supportive care products, with a focus on
utilizing its proprietary formulation technologies to address the
clinical shortcomings of existing commercial pharmaceutical products.
The company has two marketed products including Subsys, a proprietary
sublingual fentanyl spray for breakthrough pain in opioid-tolerant
cancer patients. Insys markets Subsys through its incentive-based,
cost-efficient commercial sales force. The company's lead product
candidate is Dronabinol Oral Solution, a proprietary orally
administered liquid formulation of dronabinol, which would be its
second branded supportive care product, if approved.
Forward-looking Statements
Statements included in this press release
that are not historical in nature, including, without limitation, any
statements related to the outcome of any investigation or the impact
of any investigation on Insys' business or marketing practices, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to certain risks and uncertainties, including
risks and uncertainties relating to the unpredictable nature of
governmental investigations and those described in Insys' periodic
reports filed with the Securities and Exchange Commission, that could
cause actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language and risk factors set forth
in Insys' periodic reports and documents filed with the Securities
and Exchange Com
mission, including Insys' most recent Quarterly
Reports on Form 10-Q, and Current Reports on Form 8-K. Insys claims
the protection of the safe harbor contained in the Private Securities
Litigation Reform Act of 1995 for forward-looking statements. Insys
is providing this information as of December 12, 2013, and assumes no
obligation to update or revise the information contained in this
press release whether as a result of new information, future events
or any other reason.
Subsys(R) is a registered trademark of Insys Therapeutics, Inc.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in